Integra LifeSciences (IART) Tops Q4 EPS by 4c; Offers FY23 Guidance

Integra LifeSciences (NASDAQ: IART) reported Q4 EPS of $0.94, $0.04 better than the analyst estimate of $0.90. Revenue for the quarter came in at $398 million versus the consensus estimate of $397.52 million.

GUIDANCE:

Integra LifeSciences sees FY2023 EPS of $3.43-$3.51, versus the consensus of $3.52. Integra LifeSciences sees FY2023 revenue of $1.6-1.62 billion, versus the consensus of $1.62 billion.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.

You May Also Be Interested In

• Argus Upgrades Integra LifeSciences (IART) to Buy, 'Valuations are still low'
• Goldman Sachs Starts Infratil New Zealand (IFT:NZ) at Buy
• Pfizer reaffirms 2026 guidance after CFO transition news